lundi 29 septembre 2014

Pertuzumab adds 16 months survival benefit to trastuzumab and chemotherapy treatment for HER2-positive metastatic breast cancer

Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal.

Pertuzumab adds 16 months survival benefit to trastuzumab and chemotherapy treatment for HER2-positive metastatic breast cancer

Aucun commentaire:

Enregistrer un commentaire